SCHEMBL17666282

SCHEMBL17666282

Cc1ccc(-n2cc(S(C)(=O)=O)cn2)c(C)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.38
MAPT P10636 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
GAA P10253 1/20 0.37
MELK Q14680 2/20 0.37
HTT P42858 4/20 0.36
KDM4E B2RXH2 1/20 0.36
PTGS1 P23219 2/20 0.36
PTGS2 P35354 2/20 0.36
MAPK1 P28482 1/20 0.36
TDP1 Q9NUW8 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
POLB P06746 3/20 0.36
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16982981 0.85 ALDH1A1 (0.38) NPSR1ALDH1A1MELKPTGS1PTGS2
SCHEMBL17066473 0.79 TDO2 (0.47) NPSR1MAPTALDH1A1LMNAHTT
SCHEMBL17666293 0.78 MELK (0.36) MELKPTGS1PTGS2
SCHEMBL17666311 0.73 NR1I2 (0.44) NPSR1MAPTALDH1A1MCOLN3LMNA
SCHEMBL17666300 0.72 GCG (0.40) NPSR1MAPTALDH1A1MCOLN3LMNA
SCHEMBL19412864 0.71 FLT1 (0.36) MELKPTGS1PTGS2
SCHEMBL16983112 0.71 PTGS2 (0.34) MELKPTGS1PTGS2
SCHEMBL17661855 0.71 PTGS2 (0.34) MELKPTGS1PTGS2
SCHEMBL2709538 0.68 RXRA (0.45) MAPTALDH1A1SMN1; SMN2HTTKDM4E
SCHEMBL1811416 0.68 LMNA (0.48) ALDH1A1LMNASMN1; SMN2MELKKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170002006-A1 MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-01-05 US disclosed
US-20160368923-A1 PYRIMIDINONES AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2016-12-22 US disclosed
US-9453018-B2 Pyrimidinones as factor XIa inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2016-09-27 US disclosed
US-20160096839-A1 PYRIMIDINONES AS FACTOR XIA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2016-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368923-A1 PYRIMIDINONES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F2 NPSR1 2160/4885MAPT 675/4885ALDH1A1 2800/4885
US-20170002006-A1 MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS TFPI2, F2, TFPI NPSR1 2317/4885MAPT 2248/4885ALDH1A1 4748/4885
US-20160096839-A1 PYRIMIDINONES AS FACTOR XIA INHIBITORS TFPI, TFPI2, F2 NPSR1 2160/4885MAPT 675/4885ALDH1A1 2800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.